GLP-1s and Alcohol: What the Semaglutide Trials Found

Some people report less interest in alcohol after starting a GLP-1 medicine. Randomized studies now support investigating semaglutide for alcohol use disorder, but that is different from an approved treatment indication or permission to drink without concern.

The practical questions are separate: whether semaglutide may help treat alcohol use disorder, whether drinking fits your particular health situation, and how to manage dependence safely. A promising study does not answer all three.

The small 2025 trial

A nine-week randomized trial enrolled 48 adults with alcohol use disorder who were not seeking treatment. Semaglutide reduced alcohol consumed in a laboratory self-administration task and improved some drinking outcomes, including drinks per drinking day, craving, and the trajectory of heavy drinking.¹

However, it did not significantly improve every outcome: average drinks per calendar day and the number of drinking days did not show the same treatment effect. Reporting only “people drank less” hides that distinction. The small sample and short follow-up also limit what the study establishes about longer-term recovery and uncommon harms.

This was evidence about semaglutide under study conditions, not evidence that any GLP-1 product, compounded formulation, or online low-dose program treats alcohol use disorder.

What the larger 2026 trial adds

A 26-week randomized, double-blind trial studied 108 people with both alcohol use disorder and obesity. Both groups received cognitive behavioral therapy. The semaglutide group had a larger reduction in heavy drinking days than the placebo group; the reported adjusted treatment difference was 13.7 percentage points, with a 95% confidence interval of 5.4 to 22.0 percentage points favoring semaglutide.²

That finding is encouraging, but it does not mean 13.7% of people were cured. It describes a difference in an outcome measured over time. The study was conducted at a single center, 88 participants completed treatment, and the population had obesity as well as alcohol use disorder. Its results cannot automatically be extended to everyone who drinks, people without obesity, or every medication in the class.

The behavioral treatment given to both groups matters too. These findings support further research and a clinical conversation; they do not establish a stand-alone replacement for comprehensive alcohol treatment.

GLP-1s are not approved alcohol-use medicines

Current Zepbound and Wegovy labeling does not include alcohol use disorder as an approved indication.³⁴ NIAAA describes established treatment options, including behavioral care and FDA-approved medications such as naltrexone, acamprosate, and disulfiram.⁵ Their suitability depends on the individual.

A clinician may discuss off-label treatment, but the evidence and uncertainties should be explicit. Avoid providers presenting preliminary semaglutide findings as proof that tirzepatide or a particular compounded product will produce the same effect. The semaglutide-versus-tirzepatide comparison distinguishes what direct obesity trials actually tested.

Can you drink while taking a GLP-1?

There is no single allowance that is appropriate for every reader. Relevant factors include your drinking history, liver or pancreatic disease, nausea or vomiting, nutrition, and other medicines. The absence of an alcohol-use indication is not a conclusion about your personal drinking safety.

Bring a complete medication list to the prescriber. Our drug-interaction guide explains why insulin and certain other diabetes medicines require special attention to low blood sugar. If you have persistent vomiting or cannot keep fluids down, contact the care team rather than treating the problem as a routine part of drinking on treatment.

Severe or persistent abdominal pain warrants medical assessment. The pancreatitis and gallbladder guide explains warning symptoms without assuming alcohol or the medicine must be the cause.

Reduced craving is not a withdrawal plan

If you drink heavily over a prolonged period, abruptly stopping can cause dangerous withdrawal. NIAAA advises medical help when withdrawal is a concern.⁶ A sudden reduction in the desire to drink does not make unsupervised withdrawal safe, and a GLP-1 prescription is not a detoxification plan.

Tell the clinician how much and how often you drink, whether you have had withdrawal symptoms, and what support is available. Do not delay urgent care for serious symptoms while waiting for a telehealth message.

What to ask before choosing a service

Ask whether the clinician can assess alcohol use alongside weight management, coordinate with an existing treatment team, and provide timely follow-up when symptoms change. Our provider checklist focuses on those practical access questions.

If a provider advertises an alcohol-related benefit, request the exact trial and the matching product. You should be able to distinguish a treatment offered with appropriate clinical oversight from a marketing claim built on a promising but limited research result.